文献速递支持与姑息治疗

阿片类镇痛药治疗伤害性癌痛:一项综合性综述

Opioid analgesics for nociceptive cancer pain: A comprehensive review.
PubMed 文献 · CA Cancer J Clin · 2023-12-18

该综述评估阿片类镇痛药对比安慰剂、其他阿片类、非阿片类镇痛药及非药物治疗,对背景性癌痛和爆发性癌痛的疗效与毒性。背景性癌痛安慰剂对照试验稀少,他喷他多或可待因可能优于安慰剂(中等至低确定性证据);非甾体抗炎药及丙米嗪对中重度背景性癌痛可能至少与阿片类同样有效。爆发性癌痛中,芬太尼口腔黏膜、颊黏膜、舌下或鼻内制剂优于安慰剂但毒性更常见;吗啡通常不优于其他阿片类且毒性特征不更优。

要点

  • 背景性癌痛安慰剂对照试验稀少,他喷他多或可待因可能优于安慰剂(中等至低确定性证据)。
  • 非甾体抗炎药(阿司匹林、吡罗昔康、双氯芬酸、酮咯酸)及丙米嗪对中重度背景性癌痛可能至少与阿片类同样有效。
  • 爆发性癌痛中芬太尼口腔黏膜、颊黏膜、舌下或鼻内制剂优于安慰剂但便秘和恶心等毒性更常见;吗啡通常不优于其他阿片类。

核心结论

  • 鉴于研究质量与数量有限,需要重新评估阿片类在癌痛患者中的临床效用,尤其是非生命终末期患者,并进一步探索阿片类对免疫系统功能和生活质量的影响。

研究设计与样本

  • 该综述评估阿片类镇痛药对比安慰剂、其他阿片类、非阿片类镇痛药及非药物治疗对背景性癌痛和爆发性癌痛的疗效与毒性。

主要发现

  • 背景性癌痛的安慰剂对照试验稀少,他喷他多或可待因可能比安慰剂更有效(中等确定性至低确定性证据)。
  • 非甾体抗炎药包括阿司匹林、吡罗昔康、双氯芬酸、酮咯酸以及抗抑郁药丙米嗪,对中重度背景性癌痛可能至少与阿片类同样有效。
  • 爆发性癌痛中,芬太尼口腔黏膜、颊黏膜、舌下或鼻内制剂比安慰剂更有效,但更常与毒性相关,包括便秘和恶心。
  • 吗啡在全球范围内被推荐用于癌痛治疗,但通常不优于其他阿片类,毒性特征也不更有利。
  • 研究结果的解读因所评估研究人群的异质性而复杂化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 背景性癌痛的安慰剂对照试验稀少。
  • 研究结果的解读因所评估研究人群的异质性而复杂化。
  • 研究质量与数量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pain is one of the most burdensome symptoms in people with cancer, and opioid analgesics are considered the mainstay of cancer pain management. For this review, the authors evaluated the efficacy and toxicities of opioid analgesics compared with placebo, other opioids, nonopioid analgesics, and nonpharmacologic treatments for background cancer pain (continuous and relatively constant pain present at rest), and breakthrough cancer pain (transient exacerbation of pain despite stable and adequately controlled background pain). They found a paucity of placebo-controlled trials for background cancer pain, although tapentadol or codeine may be more efficacious than placebo (moderate-certainty to low-certainty evidence). Nonsteroidal anti-inflammatory drugs including aspirin, piroxicam, diclofenac, ketorolac, and the antidepressant medicine imipramine, may be at least as efficacious as opioids for moderate-to-severe background cancer pain. For breakthrough cancer pain, oral transmucosal, buccal, sublingual, or intranasal fentanyl preparations were identified as more efficacious than placebo but were more commonly associated with toxicities, including constipation and nausea. Despite being recommended worldwide for the treatment of cancer pain, morphine was generally not superior to other opioids, nor did it have a more favorable toxicity profile. The interpretation of study results, however, was complicated by the heterogeneity in the study populations evaluated. Given the limited quality and quantity of research, there is a need to reappraise the clinical utility of opioids in people with cancer pain, particularly those who are not at the end of life, and to further explore the effects of opioids on immune system function and quality of life in these individuals.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Abdel Shaheed C, Hayes C, Maher CG, et al. Opioid analgesics for nociceptive cancer pain: A comprehensive review. CA Cancer J Clin. 2023. PMID: 38108561. doi:10.3322/caac.21823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。